On July 16, 2024, Senti Biosciences, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol SNTI, reported the entry into an amended and restated ChEF purchase agreement with Chardan Capital Markets LLC. This agreement pertains to Senti Biosciences' existing $50 million equity facility and includes updated volume weighted average price purchase mechanics to allow for Intraday VWAP Purchases. The details of the amended agreement were summarized in the company's Form 8-K filing with the SEC, with the full text of the agreement attached as Exhibit 10.1. Senti Biosciences, identified as an emerging growth company, has also elected not to use the extended transition period for complying with new or revised financial accounting standards. The company's CEO, Timothy Lu, M.D., Ph.D., signed the SEC filing on the same day, affirming the company's compliance with the Securities Exchange Act of 1934.

On July 16, 2024, Senti Biosciences, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol SNTI, reported the entry into an amended and restated ChEF purchase agreement with Chardan Capital Markets LLC. This agreement pertains to Senti Biosciences' existing $50 million equity facility and includes updated volume weighted average price purchase mechanics to allow for Intraday VWAP Purchases. The details of the amended agreement were summarized in the company's Form 8-K filing with the SEC, with the full text of the agreement attached as Exhibit 10.1. Senti Biosciences, identified as an emerging growth company, has also elected not to use the extended transition period for complying with new or revised financial accounting standards. The company's CEO, Timothy Lu, M.D., Ph.D., signed the SEC filing on the same day, affirming the company's compliance with the Securities Exchange Act of 1934.